Last reviewed · How we verify
Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide
Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide is a Small molecule drug developed by Hackensack Meridian Health. It is currently in Phase 2 development. Also known as: FCR + Lenalidomide.
At a glance
| Generic name | Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide |
|---|---|
| Also known as | FCR + Lenalidomide |
| Sponsor | Hackensack Meridian Health |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma (PHASE3)
- Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (PHASE3)
- Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma (PHASE1)
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia (PHASE2)
- Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide (PHASE2)
- NK Cells in Cord Blood Transplantation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide CI brief — competitive landscape report
- Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide updates RSS · CI watch RSS
- Hackensack Meridian Health portfolio CI
Frequently asked questions about Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide
What is Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide?
Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide is a Small molecule drug developed by Hackensack Meridian Health.
Who makes Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide?
Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide is developed by Hackensack Meridian Health (see full Hackensack Meridian Health pipeline at /company/hackensack-meridian-health).
Is Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide also known as anything else?
Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide is also known as FCR + Lenalidomide.
What development phase is Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide in?
Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide is in Phase 2.
Related
- Manufacturer: Hackensack Meridian Health — full pipeline
- Also known as: FCR + Lenalidomide
- Compare: Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide vs similar drugs
- Pricing: Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide cost, discount & access